BACKGROUND: Statins have been proposed to reduce the risk of Alzheimer's disease (AD). OBJECTIVE: Assess whether long-term statin use was associated with neuroimaging biomarkers of aging and dementia. METHODS: Methods: We analyzed neuroimaging biomarkers in 1,160 individuals aged 65+ from the Mayo Clinic Study of Aging, a population-based prospective longitudinal study of cognitive aging. RESULTS: Statin-treated (5+ years of therapy) individuals had greater burden of mid-and late-life cardiovascular disease (p < 0.001) than statin-untreated (≤3 months) individuals. Lower fractional anisotropy in the genu of the corpus callosum, an early marker of cerebrovascular disease, was associated with long-term statin exposure (p < 0.035). No significant associations were identified between long-term statin exposure and cerebral amyloid or tau burden, AD pattern neurodegeneration, or white matter hyperintensity burden. CONCLUSIONS: Long-term statin therapy was not associated with differences in AD biomarkers. Individuals with long-term statin exposure had worse white matter integrity in the genu of the corpus callosum, consistent with the coexistence of higher cerebrovascular risk factor burden in this group.
BACKGROUND: Statins have been proposed to reduce the risk of Alzheimer's disease (AD). OBJECTIVE: Assess whether long-term statin use was associated with neuroimaging biomarkers of aging and dementia. METHODS: Methods: We analyzed neuroimaging biomarkers in 1,160 individuals aged 65+ from the Mayo Clinic Study of Aging, a population-based prospective longitudinal study of cognitive aging. RESULTS: Statin-treated (5+ years of therapy) individuals had greater burden of mid-and late-life cardiovascular disease (p < 0.001) than statin-untreated (≤3 months) individuals. Lower fractional anisotropy in the genu of the corpus callosum, an early marker of cerebrovascular disease, was associated with long-term statin exposure (p < 0.035). No significant associations were identified between long-term statin exposure and cerebral amyloid or tau burden, AD pattern neurodegeneration, or white matter hyperintensity burden. CONCLUSIONS: Long-term statin therapy was not associated with differences in AD biomarkers. Individuals with long-term statin exposure had worse white matter integrity in the genu of the corpus callosum, consistent with the coexistence of higher cerebrovascular risk factor burden in this group.
Entities:
Keywords:
Alzheimer’s disease; amyloid; biomarkers; cerebrovascular disease; magnetic resonance imaging; neurodegeneration; positron emission tomography; statins; tau; white matter
Authors: G Li; E B Larson; J A Sonnen; J B Shofer; E C Petrie; A Schantz; E R Peskind; M A Raskind; J C S Breitner; T J Montine Journal: Neurology Date: 2007-08-28 Impact factor: 9.910
Authors: Jennifer L St Sauver; Brandon R Grossardt; Barbara P Yawn; L Joseph Melton; Joshua J Pankratz; Scott M Brue; Walter A Rocca Journal: Int J Epidemiol Date: 2012-11-18 Impact factor: 7.196
Authors: Kejal Kantarci; Christopher G Schwarz; Robert I Reid; Scott A Przybelski; Timothy G Lesnick; Samantha M Zuk; Matthew L Senjem; Jeffrey L Gunter; Val Lowe; Mary M Machulda; David S Knopman; Ronald C Petersen; Clifford R Jack Journal: JAMA Neurol Date: 2014-12 Impact factor: 18.302
Authors: Rosebud O Roberts; David S Knopman; Scott A Przybelski; Michelle M Mielke; Kejal Kantarci; Gregory M Preboske; Matthew L Senjem; Vernon S Pankratz; Yonas E Geda; Bradley F Boeve; Robert J Ivnik; Walter A Rocca; Ronald C Petersen; Clifford R Jack Journal: Neurology Date: 2014-03-19 Impact factor: 9.910
Authors: Iain D Croall; Valerie Lohner; Barry Moynihan; Usman Khan; Ahamad Hassan; John T O'Brien; Robin G Morris; Daniel J Tozer; Victoria C Cambridge; Kirsty Harkness; David J Werring; Andrew M Blamire; Gary A Ford; Thomas R Barrick; Hugh S Markus Journal: Clin Sci (Lond) Date: 2017-06-07 Impact factor: 6.124
Authors: Christopher G Schwarz; Robert I Reid; Jeffrey L Gunter; Matthew L Senjem; Scott A Przybelski; Samantha M Zuk; Jennifer L Whitwell; Prashanthi Vemuri; Keith A Josephs; Kejal Kantarci; Paul M Thompson; Ronald C Petersen; Clifford R Jack Journal: Neuroimage Date: 2014-03-18 Impact factor: 6.556
Authors: Taylor J Krivanek; Seth A Gale; Brittany M McFeeley; Casey M Nicastri; Kirk R Daffner Journal: J Alzheimers Dis Date: 2021 Impact factor: 4.472
Authors: Michelle M Mielke; Scott A Przybelski; Timothy G Lesnick; Silke Kern; Henrik Zetterberg; Kaj Blennow; David S Knopman; Jonathan Graff-Radford; Ronald C Petersen; Clifford R Jack; Prashanthi Vemuri Journal: Alzheimers Dement Date: 2021-03-04 Impact factor: 16.655
Authors: Michelle M Mielke; Jeremy A Syrjanen; Kaj Blennow; Henrik Zetterberg; Prashanthi Vemuri; Ingmar Skoog; Mary M Machulda; Walter K Kremers; David S Knopman; Clifford Jack; Ronald C Petersen; Silke Kern Journal: Neurology Date: 2019-06-10 Impact factor: 9.910
Authors: Jordan D Marks; Jeremy A Syrjanen; Jonathan Graff-Radford; Ronald C Petersen; Mary M Machulda; Michelle R Campbell; Alicia Algeciras-Schimnich; Val Lowe; David S Knopman; Clifford R Jack; Prashanthi Vemuri; Michelle M Mielke Journal: Alzheimers Res Ther Date: 2021-12-14 Impact factor: 6.982
Authors: Luipa Khandker; Marisa A Jeffries; Yun-Juan Chang; Marie L Mather; Angelina V Evangelou; Jennifer N Bourne; Azadeh K Tafreshi; Isis M Ornelas; Ozlem Bozdagi-Gunal; Wendy B Macklin; Teresa L Wood Journal: Cell Rep Date: 2022-03-01 Impact factor: 9.423
Authors: Nicholas M Vogt; Jack F V Hunt; Yue Ma; Carol A Van Hulle; Nagesh Adluru; Richard J Chappell; Karen K Lazar; Laura E Jacobson; Benjamin P Austin; Sanjay Asthana; Sterling C Johnson; Barbara B Bendlin; Cynthia M Carlsson Journal: Ann Clin Transl Neurol Date: 2021-07-18 Impact factor: 4.511